These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20549827)

  • 1. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
    Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
    Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
    Morales L; Pans S; Paridaens R; Westhovens R; Timmerman D; Verhaeghe J; Wildiers H; Leunen K; Amant F; Berteloot P; Smeets A; Van Limbergen E; Weltens C; Van den Bogaert W; De Smet L; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2007 Jul; 104(1):87-91. PubMed ID: 17061044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
    Roberts K; Rickett K; Greer R; Woodward N
    Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
    Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
    Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
    Lintermans A; Laenen A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    Ann Oncol; 2013 Feb; 24(2):350-355. PubMed ID: 23038762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
    Henry NL; Giles JT; Ang D; Mohan M; Dadabhoy D; Robarge J; Hayden J; Lemler S; Shahverdi K; Powers P; Li L; Flockhart D; Stearns V; Hayes DF; Storniolo AM; Clauw DJ
    Breast Cancer Res Treat; 2008 Sep; 111(2):365-72. PubMed ID: 17922185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
    Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
    Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
    Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
    Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
    Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
    Stearns V; Jegede OA; Chang VT; Skaar TC; Berenberg JL; Nand R; Shafqat A; Jacobs NL; Luginbuhl W; Gilman P; Benson AB; Goodman JR; Buchschacher GL; Henry NL; Loprinzi CL; Flynn PJ; Mitchell EP; Fisch MJ; Sparano JA; Wagner LI
    Clin Cancer Res; 2024 Jul; 30(13):2709-2718. PubMed ID: 38640040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
    Bao T; Cai L; Giles JT; Gould J; Tarpinian K; Betts K; Medeiros M; Jeter S; Tait N; Chumsri S; Armstrong DK; Tan M; Folkerd E; Dowsett M; Singh H; Tkaczuk K; Stearns V
    Breast Cancer Res Treat; 2013 Feb; 138(1):167-74. PubMed ID: 23393007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
    Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
    Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
    Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.
    Peng N; Zhang Y; Ma C; Yu MW; Yang GW; Fu Q; Xu WR; Wang XM
    Trials; 2014 May; 15():171. PubMed ID: 24885324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
    Singer O; Cigler T; Moore AB; Levine AB; Hentel K; Belfi L; Do HT; Mandl LA
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
    Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.